What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Respiratory

PUBLISHER: DelveInsight | PRODUCT CODE: 1129044

PUBLISHER: DelveInsight | PRODUCT CODE: 1129044

Progressive Pulmonary Fibrosis (PPF)- Epidemiology Forecast-2032

PUBLISHED: September 1, 2022

PAGES: 70 Pages

DELIVERY TIME: 1-3 business days

ADD TO COMPARE

SELECT AN OPTION

DelveInsight's 'Progressive pulmonary fibrosis (PPF)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Progressive pulmonary fibrosis (PPF), historical and forecasted epidemiology as well as the PPF trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Progressive pulmonary fibrosis (PPF) Disease Understanding

Progressive pulmonary fibrosis (PPF) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.

Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.

Progressive pulmonary fibrosis (PPF) are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The type-specific segmentation majorly includes, Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs.

Progressive pulmonary fibrosis (PPF) Diagnosis

Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), is key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive pulmonary fibrosis (PPF) is calculated on the basis of FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.

The differential diagnosis of Interstitial Lung Diseases requires a multidisciplinary approach, usually involving pulmonologist, radiologist, and pathologist. The evaluations include clinical presentation, specific history assessment, smoking status, lung function evaluation, serological test results, imaging and if required, lung biopsy.

Continued in the report…..

Progressive pulmonary fibrosis (PPF) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Total Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of ILD, Type-specific Diagnosed Prevalent Cases of ILD, and Total Diagnosed Prevalent Cases of Progressive pulmonary fibrosis (PPF), in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, from 2019 to 2032.

Progressive pulmonary fibrosis (PPF) Detailed Epidemiology Segmentation

In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) in the 7MM were 127,754 in 2021.
The highest total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) were accounted by the US in 2021 (71,657 cases), which are expected to show a rise in the future.
Among the European countries, Germany had the highest diagnosed prevalent cases of PPF with 11,115 cases, followed by the United Kingdom, which had prevalent population of 9,872 in 2021. On the other hand, Spain had the lowest prevalent population (6,401 cases).
Japan had 10,296 total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) in 2021, accounting for approximately 8% in 7MM.

Scope of the Report:

The report covers the descriptive overview of Progressive pulmonary fibrosis (PPF), explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden of Progressive pulmonary fibrosis (PPF).
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Report Highlights:

11-Year Forecast of Progressive pulmonary fibrosis (PPF)
7MM Coverage
Total Diagnosed Prevalent Cases of Progressive pulmonary fibrosis (PPF)

Key Questions Answered

What are the disease risk and burden of Progressive pulmonary fibrosis (PPF)?
What is the historical Progressive pulmonary fibrosis (PPF) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
What would be the forecasted patient pool of Progressive pulmonary fibrosis (PPF) at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Progressive pulmonary fibrosis (PPF)?
Out of the above-mentioned countries, which country would have the highest prevalent population of Progressive pulmonary fibrosis (PPF) during the forecast period (2022-2032)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to buy:

The Progressive pulmonary fibrosis (PPF) report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the 7MM+ Progressive pulmonary fibrosis (PPF) epidemiology forecast.
The Progressive pulmonary fibrosis (PPF) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The Progressive pulmonary fibrosis (PPF) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

Patient Segmentation
Disease Risk and Burden
Risk of Disease by segmentation
Factors driving growth in a specific patient population

Geographies Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019-2032

Product Code: DIEI1729

1. Key Insights

2. Report Introduction

3. Progressive pulmonary fibrosis (PPF) Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of PPF by Therapies in 2019
3.2. Patient Share (%) Distribution of PPF by Therapies in 2032

4. Progressive pulmonary fibrosis (PPF): Future Perspective

5. Executive Summary of Progressive pulmonary fibrosis (PPF)

6. Key Events

7. Disease Background and Overview

7.1. Introduction
7.2. Types of ILDs progressing into PPF
- 7.2.1. Chronic hypersensitivity pneumonitis (HP)
- 7.2.2. Idiopathic nonspecific interstitial pneumonia (INSIP)
- 7.2.3. Unclassifiable idiopathic interstitial pneumonia (unclassifiable IIPs)
- 7.2.4. Autoimmune interstitial lung diseases (CTD-ILDs)
- 7.2.5. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
- 7.2.6. SSc-ILD
- 7.2.7. Connective tissue disease less commonly associated with PPF
- 7.2.8. Chronic sarcoidosis
- 7.2.9. Exposure-related ILDs
7.3. Pathogenesis of PPF
7.4. Predictors of Disease Progression
7.5. Diagnosis of Progressive-Fibrosing Interstitial Lung Disease (PPF)
7.6. Diagnostic Algorithm of PPF

8. Epidemiology and Patient Population

8.1. Key Findings
8.2. Methodology of Epidemiology
8.3. Assumptions and Rationale: 7MM
- 8.3.1. United States
- 8.3.2. EU5 Countries
- 8.3.3. Japan
8.4. Total Diagnosed Prevalent Cases of Progressive pulmonary fibrosis (PPF) in the 7MM
8.5. Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease in the 7MM
8.6. The United States
- 8.6.1. Total Prevalent Cases of ILD in the United States
- 8.6.2. Total Diagnosed Prevalent Cases of ILD in the United States
- 8.6.3. Type-specific Diagnosed Prevalent Cases of ILD in the United States
- 8.6.4. Total Diagnosed Prevalent cases of PPF in the United States
8.7. Major Five European Countries
- 8.7.1. Germany
  - 8.7.1.1. Total Prevalent Cases of ILD
  - 8.7.2.2. Total Diagnosed Prevalent Cases of ILD
  - 8.7.3.3. Type-specific Diagnosed Prevalent Cases of ILD
  - 8.7.4.4. Total Diagnosed Prevalent cases of PPF
- 8.7.2. France
  - 8.7.2.1. Total Prevalent Cases of ILD
  - 8.7.2.2. Total Diagnosed Prevalent Cases of ILD
  - 8.7.2.3. Type-specific Diagnosed Prevalent Cases of ILD
  - 8.7.2.4. Total Diagnosed Prevalent cases of PPF
- 8.7.3. Italy
  - 8.7.3.1. Total Prevalent Cases of ILD
  - 8.7.3.2. Total Diagnosed Prevalent Cases of ILD
  - 8.7.3.3. Type-specific Diagnosed Prevalent Cases of ILD
  - 8.7.3.4. Total Diagnosed Prevalent cases of PPF
- 8.7.4. Spain
  - 8.7.4.1. Total Prevalent Cases of ILD
  - 8.7.4.2. Total Diagnosed Prevalent Cases of ILD
  - 8.7.4.3. Type-specific Diagnosed Prevalent Cases of ILD
  - 8.7.4.4. Total Diagnosed Prevalent cases of PPF
- 8.7.5. The United Kingdom
  - 8.7.5.1. Total Prevalent Cases of ILD
  - 8.7.5.2. Total Diagnosed Prevalent Cases of ILD
  - 8.7.5.3. Type-specific Diagnosed Prevalent Cases of ILD
  - 8.7.5.4. Total Diagnosed Prevalent cases of PPF
8.8. Japan
- 8.8.1. Total Prevalent Cases of ILD in Japan
- 8.8.2. Total Diagnosed Prevalent Cases of ILD in Japan
- 8.8.3. Type-specific Diagnosed Prevalent Cases of ILD in Japan
- 8.8.4. Total Diagnosed Prevalent cases of PPF in Japan

9. Patient Journey

10. Key Opinion Leaders' Views

11. Appendix

11.1. Bibliography
11.2. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

Product Code: DIEI1729

List of Tables

Table 1: Total Diagnosed Prevalent cases of PPF in the 7MM (2019-2032)
Table 2: Type-specific Diagnosed Prevalent Cases of ILD in the 7MM (2019-2032)
Table 3: Total Prevalent Cases of ILD in the US (2019-2032)
Table 4: Total Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Table 5: Type-specific Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Table 6: Total Diagnosed Prevalent Cases of PPF in the US (2019-2032)
Table 7: Total Prevalent Cases of ILD in Germany (2019-2032)
Table 8: Total Diagnosed Prevalent Cases of ILD in Germany (2019-2032)
Table 9: Type-specific Diagnosed Prevalent Cases of ILD in Germany (2019-2032)
Table 10: Total Diagnosed Prevalent Cases of PPF in Germany (2019-2032)
Table 11: Total Prevalent Cases of ILD in France (2019-2032)
Table 12: Total Diagnosed Prevalent Cases of ILD in France (2019-2032)
Table 13: Type-specific Diagnosed Prevalent Cases of ILD in France (2019-2032)
Table 14: Total Diagnosed Prevalent Cases of PPF in France (2019-2032)
Table 15: Total Prevalent Cases of ILD in Italy (2019-2032)
Table 16: Total Diagnosed Prevalent Cases of ILD in Italy (2019-2032)
Table 17: Type-specific Diagnosed Prevalent Cases of ILD in Italy (2019-2032)
Table 18: Total Diagnosed Prevalent Cases of PPF in Italy (2019-2032)
Table 19: Total Prevalent Cases of ILD in Spain (2019-2032)
Table 20: Total Diagnosed Prevalent Cases of ILD in Spain (2019-2032)
Table 21: Type-specific Diagnosed Prevalent Cases of ILD in Spain (2019-2032)
Table 22: Total Diagnosed Prevalent Cases of PPF in Spain (2019-2032)
Table 23: Total Prevalent Cases of ILD in the UK (2019-2032)
Table 24: Total Diagnosed Prevalent Cases of ILD in the UK (2019-2032)
Table 25: Type-specific Diagnosed Prevalent Cases of ILD in the UK (2019-2032)
Table 26: Total Diagnosed Prevalent Cases of PPF in the UK (2019-2032)
Table 27: Total Prevalent Cases of ILD in the EU5 (2019-2032)
Table 28: Total Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Table 29: Type-specific Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Table 30: Total Diagnosed Prevalent Cases of PPF in the EU5 (2019-2032)
Table 31: Total Prevalent Cases of ILD in Japan (2019-2032)
Table 32: Total Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Table 33: Type-specific Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Table 34: Total Diagnosed Prevalent Cases of PPF in Japan (2019-2032)
Table 35: List of Abbreviations

List of Figures

Figure 1: Total Diagnosed Prevalent cases of PPF in the 7MM (2019-2032)
Figure 2: Type-specific Diagnosed Prevalent Cases of ILD in the 7MM (2019-2032)
Figure 3: Total Prevalent Cases of ILD in the US (2019-2032)
Figure 4: Total Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Figure 5: Type-specific Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Figure 6: Total Diagnosed Prevalent Cases of PPF in the US (2019-2032)
Figure 7: Total Prevalent Cases of ILD in Germany (2019-2032)
Figure 8: Total Diagnosed Prevalent Cases of ILD in Germany (2019-2032)
Figure 9: Type-specific Diagnosed Prevalent Cases of ILD in Germany (2019-2032)
Figure 10: Total Diagnosed Prevalent Cases of PPF in Germany (2019-2032)
Figure 11: Total Prevalent Cases of ILD in France (2019-2032)
Figure 12: Total Diagnosed Prevalent Cases of ILD in France (2019-2032)
Figure 13: Type-specific Diagnosed Prevalent Cases of ILD in France (2019-2032)
Figure 14: Total Diagnosed Prevalent Cases of PPF in France (2019-2032)
Figure 15: Total Prevalent Cases of ILD in Italy (2019-2032)
Figure 16: Total Diagnosed Prevalent Cases of ILD in Italy (2019-2032)
Figure 17: Type-specific Diagnosed Prevalent Cases of ILD in Italy (2019-2032)
Figure 18: Total Diagnosed Prevalent Cases of PPF in Italy (2019-2032)
Figure 19: Total Prevalent Cases of ILD in Spain (2019-2032)
Figure 20: Total Diagnosed Prevalent Cases of ILD in Spain (2019-2032)
Figure 21: Type-specific Diagnosed Prevalent Cases of ILD in Spain (2019-2032)
Figure 22: Total Diagnosed Prevalent Cases of PPF in Spain (2019-2032)
Figure 23: Total Prevalent Cases of ILD in the UK (2019-2032)
Figure 24: Total Diagnosed Prevalent Cases of ILD in the UK (2019-2032)
Figure 25: Type-specific Diagnosed Prevalent Cases of ILD in the UK (2019-2032)
Figure 26: Total Diagnosed Prevalent Cases of PPF in the UK (2019-2032)
Figure 27: Total Prevalent Cases of ILD in the EU5 (2019-2032)
Figure 28: Total Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Figure 29: Type-specific Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Figure 30: Total Diagnosed Prevalent Cases of PPF in the EU5 (2019-2032)
Figure 31: Total Prevalent Cases of ILD in Japan (2019-2032)
Figure 32: Total Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Figure 33: Type-specific Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Figure 34: Total Diagnosed Prevalent Cases of PPF in Japan (2019-2032)
Figure 35: List of Abbreviations